Nicholas J. Schork, Ph.D., an international authority over human longevity and health maintenance, joined Honorhealth Research Institute as research director of longevity, prevention and interception.
Dr. Schork directs a single laboratory which is part of the new Translational Science Center of the Research Institute, and its appointment is part of a significant thrust of the Institute to extend its collaborations and the field of precision medicine possibilities; Provide specific responses to individual patients with rare or difficult to treat disease.
“It is a question of optimizing people’s health,” said Dr. Schork, who has trained and worked in some of the country’s main health research establishments.
The disease is not like an out and over switch; One day, you have no illness and the next day, you have an illness as by magic. There are processes that take place over time that contribute to the disease or reflect pathobiology behind the disease. Research by focusing on interception is trying to understand these processes to the point where we can intervene on them, rather than the manifest manifestations of the disease. “”
Nicholas J. Schork, PHD, research director of longevity, prevention and interception, Honorhealth Research Institute
How medical interception works
For example, before treating a patient with a certain type of medication once he has developed specific cancer, doctors in the future could use new high -tech surveillance of the genome of a person or a type of body fluid such as blood, saliva or even cerebral vertebral fluid to find biomarkers who would indicate early for who could be at risk of cancer.
These advanced interception warnings could also be affected through the use of portable devices, imaging protocols – or anything that could provide more frequent surveillance. The doctor could then recommend specific actions or drugs that an individual could take to avoid cancer completely before he occurs and puts his overall health in danger.
Dr. Schork said that he would also use the use of artificial intelligence to question major electronic health files with billions of data points to synthesize complex information and propose recommendations based on the identification of models invisible to human clinicians.
“The first AI assessments show the potential to improve the accuracy of the diagnosis, reduce errors and personalize care pathways, provided they are validated in rigorous clinical circles,” he said, pointing to the need for clinical efforts to strengthen translation and translational science discoveries to practice with clinical patients.
HonorHealth Leadership enthousiaste
In welcoming Dr. Schork and his expertise to HonorHealth, Michael Gordon, MD, FASCO, Medical Director of the Research Institute, said: « Ultimately, it’s all about living longer, living better, reducing the risk of disease and promoting longevity. We want to emphasize prevention and interception – whether it’s intercepting in the evolution of cardiovascular disease or intercepting in the evolution of cancer – we want to find more and more sensitive ways Diagnostiquer la maladie plus tôt;
Mark Slater, PH.D., CEO of the Research Institute, and Vice-President of Research for Honorhealth, said that Dr. Schork brings with him a wealth of collaborators and facilitators across the country and around the world, who, among others, will strengthen the institute’s partnership with the new school of medicine and advanced medical engineering of Arizona State University.
“Nik is a brilliant spirit that has really been at the forefront of the development of new innovations and technologies,” said Dr. Slater. “He is a great scientist of data and a person in the digital and computer space that has gathered basic and translational science in the clinical world through a number of different diseases. »»
Sunil Sharma, MD, MBA, director of the Center for Translational Science, said: “I have known Dr. Schork for several years now. He is a true man of the Renaissance and I deeply appreciate his unique investigation capacities, his scientific rigor and his imagination.
Dr. Schork research context
More recently, Dr. Schork has held the posts of a distinguished professor and director of the clinical genomic division and therapeutics at the Translational Genomics Research Institute (TGEN) of Phoenix, a frequent collaborator of clinical trials with the Institute.
He also owned the titles of: Auxiliary professor of the population sciences as well as molecular and cellular biology at City of Hope; Auxiliary professor of psychiatry and biostatistics at the University of California San Diego; and auxiliary professor of structural and integrating computer biology at the Research Institute scripps.
Before these positions, Dr. Schork was a professor and director of human biology at J. Craig Ventier Institute; Professor, molecular and experimental medicine, at Scripps Research, and director of bioinformatics and biostatis of the Translational Science Institute scripps. Dr. Schork also organized meetings at the faculty at Case Western Reserve University and Harvard University.
Dr. Schork has published more than 600 articles in many areas of biomedical science and translation, including articles detailing new methodologies and applications taking advantage of integrated approaches for the diagnosis, treatment and prevention of diseases, as well as the design of clinical trials. He also has a long history of collaborative research and linked to the consortium in which he contributed to the analysis methodology and to an applied data analysis expertise.
